Bristol-Myers Squibb Co
BMY47.950USD
-1.870-3.75%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
96.19BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Bristol-Myers Squibb Co Unternehmen
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
Unternehmensinformationen
Unternehmens-codeBMY
Name des UnternehmensBristol-Myers Squibb Co
IPO-datumJul 05, 1929
Gegründet am1933
CEODr. Christopher S. (Chris) Boerner, Ph.D.
Anzahl der mitarbeiter34100
WertpapierartOrdinary Share
GeschäftsjahresendeJul 05
AddresseRoute 206 And Province Line Road
StadtPRINCETON
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl08543
Telefon16092524621
Websitehttps://www.bms.com
Unternehmens-codeBMY
IPO-datumJul 05, 1929
Gegründet am1933
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Sandra Leung
Ms. Sandra Leung
Executive Vice President, General Counsel, Member of the Leadership Team
Executive Vice President, General Counsel, Member of the Leadership Team
465.37K
+3.85%
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
125.44K
+19.89%
Mr. Samit Hirawat, M.D.
Mr. Samit Hirawat, M.D.
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
79.26K
+23.98%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
14.97K
+27.27%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, Corporate Affairs, Member of the Leadership Team
Executive Vice President, Corporate Affairs, Member of the Leadership Team
8.32K
+65.81%
Mr. Robert Plenge, M.D., Ph.D.
Mr. Robert Plenge, M.D., Ph.D.
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
--
--
Mr. Benjamin Hickey
Mr. Benjamin Hickey
President - RayzeBio Organization, Member of the Leadership Team
President - RayzeBio Organization, Member of the Leadership Team
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Sandra Leung
Ms. Sandra Leung
Executive Vice President, General Counsel, Member of the Leadership Team
Executive Vice President, General Counsel, Member of the Leadership Team
465.37K
+3.85%
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
125.44K
+19.89%
Mr. Samit Hirawat, M.D.
Mr. Samit Hirawat, M.D.
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
79.26K
+23.98%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
14.97K
+27.27%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Eliquis
13.33B
27.60%
Opdivo
9.30B
19.26%
Revlimid
5.77B
11.95%
Orencia
3.68B
7.62%
Pomalyst/Imnovid
3.54B
7.34%
Other
12.66B
26.22%
Nach RegionUSD
Name
Umsatz
Anteil
United States
34.10B
70.61%
International
13.20B
27.33%
other
996.00M
2.06%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Eliquis
13.33B
27.60%
Opdivo
9.30B
19.26%
Revlimid
5.77B
11.95%
Orencia
3.68B
7.62%
Pomalyst/Imnovid
3.54B
7.34%
Other
12.66B
26.22%
Aktionäre
Update-Zeit: Tue, Apr 22
Update-Zeit: Tue, Apr 22
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
9.29%
BlackRock Institutional Trust Company, N.A.
4.77%
State Street Global Advisors (US)
4.68%
JP Morgan Asset Management
3.10%
Charles Schwab Investment Management, Inc.
2.96%
Other
75.20%
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
9.29%
BlackRock Institutional Trust Company, N.A.
4.77%
State Street Global Advisors (US)
4.68%
JP Morgan Asset Management
3.10%
Charles Schwab Investment Management, Inc.
2.96%
Other
75.20%
Art
Aktionäre
Anteil
Investment Advisor
36.70%
Investment Advisor/Hedge Fund
32.54%
Research Firm
2.85%
Pension Fund
2.49%
Bank and Trust
2.25%
Sovereign Wealth Fund
1.85%
Hedge Fund
1.70%
Insurance Company
0.16%
Individual Investor
0.05%
Other
19.42%
Institutionelle Beteiligung
Update-Zeit: Sun, Jan 19
Update-Zeit: Sun, Jan 19
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
4166
1.65B
80.98%
+21.82M
2024Q4
4261
1.65B
81.14%
+17.04M
2024Q3
4116
1.60B
78.69%
-22.73M
2024Q2
4105
1.59B
78.35%
-83.12M
2024Q1
4118
1.64B
80.97%
+13.32M
2023Q4
4115
1.60B
78.83%
-46.39M
2023Q3
4042
1.63B
77.83%
-55.50M
2023Q2
4082
1.66B
78.77%
-34.93M
2023Q1
4110
1.66B
78.74%
-34.09M
2022Q4
4105
1.66B
77.92%
-72.60M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
189.02M
9.29%
+1.40M
+0.75%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
97.01M
4.77%
-7.46M
-7.14%
Dec 31, 2024
State Street Global Advisors (US)
95.14M
4.68%
+2.25M
+2.42%
Dec 31, 2024
JP Morgan Asset Management
63.10M
3.1%
+12.35M
+24.34%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
60.30M
2.96%
-729.93K
-1.20%
Dec 31, 2024
Capital International Investors
45.87M
2.25%
+3.22M
+7.55%
Dec 31, 2024
Geode Capital Management, L.L.C.
44.39M
2.18%
+1.19M
+2.75%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
35.18M
1.73%
+2.58M
+7.92%
Dec 31, 2024
Columbia Threadneedle Investments (US)
28.50M
1.4%
+12.26M
+75.55%
Dec 31, 2024
Fidelity Management & Research Company LLC
27.55M
1.35%
-9.07M
-24.78%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
First Trust NASDAQ Pharmaceuticals ETF
10.07%
VanEck Morningstar Wide Moat Value ETF
5.06%
Invesco Pharmaceuticals ETF
5.02%
Global X US Cash Flow Kings 100 ETF
4.97%
Invesco S&P Ultra Dividend Revenue ETF
4.9%
VictoryShares Free Cash Flow ETF
4.81%
VanEck Pharmaceutical ETF
4.81%
Cullen Enhanced Equity Income ETF
4.53%
Tema Oncology ETF
4.47%
iShares U.S. Pharmaceuticals ETF
4.38%
Mehr Anzeigen
First Trust NASDAQ Pharmaceuticals ETF
Anteil10.07%
VanEck Morningstar Wide Moat Value ETF
Anteil5.06%
Invesco Pharmaceuticals ETF
Anteil5.02%
Global X US Cash Flow Kings 100 ETF
Anteil4.97%
Invesco S&P Ultra Dividend Revenue ETF
Anteil4.9%
VictoryShares Free Cash Flow ETF
Anteil4.81%
VanEck Pharmaceutical ETF
Anteil4.81%
Cullen Enhanced Equity Income ETF
Anteil4.53%
Tema Oncology ETF
Anteil4.47%
iShares U.S. Pharmaceuticals ETF
Anteil4.38%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
22.71B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
Jun 14, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option
Jul 07, 2023
Aug 01, 2023
Jul 06, 2023
Mar 03, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023
Apr 10, 2023
May 01, 2023
Apr 06, 2023
Dec 08, 2022
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023
Jan 06, 2023
Feb 01, 2023
Jan 05, 2023
Sep 14, 2022
BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022
Oct 07, 2022
Nov 01, 2022
Oct 06, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten